In a new research published by Drug Safety, Seegnal’s platform proved superior in every criterion compared to EPIC, thanks to its ability to personalize alerting based on hundreds of patient-specific and medication-specific factors.
Seegnal was compared, head-to-head, with EPIC’s drug-related problems’ alerting, and massively outperformed it by introducing groundbreaking accuracy (e.g., 99% specificity in Seegnal vs. 0.3% in EPIC), patient-specific alerts and real-time consideration of unique and exclusive domains (e.g., multi-drug assessments, lab results, renal functions, pharmacogenetics, smoking impacts). All these, while diminishing alert fatigue and reducing alert load by twentyfold vs. EPIC, in both the inpatient and an outpatient setting.
The study was performed at Brigham and Women’s Hospital (BWH), Boston, MA, USA, a large urban academic medical center that uses a leading vendor EHR system, EPIC. The researchers noted that Seegnal’s performance is attributed mostly to its ability to personalize alerting because of its real-time consideration of up to hundreds of patient-specific and medication-specific attributes. They also noted that the platform could help notify physicians of number of new potential ADEs, and—based on the chart review—69% of these potentially could be prevented.
Upon the study’s publication, Roni Shiloh, Seegnal’s Founder & CEO said “Seegnal’s platform has once again proven the value of including patient- and medication-specific attributes in alerting algorithms. We already know that overloading clinicians with irrelevant alerts and alert fatigue can severely impair physician’s ability to prevent serious drug-related problems. This study, along with the constant feedback we receive from our users, strengthens our belief that using Seegnal substantially reduces complications, hospitalizations & healthcare expenditures, greatly enhances clinicians’ satisfaction and most important – saves lives.”
Read the full research here